SL-172154 Receives FDA Orphan Drug Designation in AML

SL-172154 has been granted orphan drug designation from the FDA in acute myeloid leukemia.

Related Keywords

,Taylor Schreiber ,International Prognostic Scoring System ,Shattuck Labs Inc ,Drug Administration ,European Hematology Association Congress ,Shattuck Labs ,Hematology Association Congress ,